GL
ICPT

GLG LLC’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

GLG LLC’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-72,047
Closed -$11.9M – 600
2015
Q3 		$11.9M Sell
72,047
-1,882
-3% -$414K 0.3% 88
2015
Q2 		$17.8M Buy
73,929
+40,168
+119% +$10.7M 0.38% 75
2015
Q1 		$9.52M Buy
+33,761
New +$7.31M 0.27% 99

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GLG LLC's ICPT Position: Q4 2015 in Review

GLG LLC sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2015, closing a stake of 72,047 shares — an estimated $11.9M sold.

GLG LLC first reported a position in ICPT in Q1 2015 and held it in 3 quarters. The position peaked at $17.8M in Q2 2015. 172 funds tracked by Wall St. Rank hold ICPT as of Q4 2015.

  • GLG LLC reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • GLG LLC sold 72,047 Intercept Pharmaceuticals, Inc. shares in Q4 2015, an estimated $11.9M.
  • GLG LLC first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2015 and held it in 3 quarters.
  • GLG LLC's Intercept Pharmaceuticals, Inc. position peaked at $17.8M in Q2 2015.
  • 172 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2015.

Based on GLG LLC's 13F filing for Q4 2015, filed 16 Feb 2016.